White paper on Ivermectin as a potential therapy for COVID-19
Agam Vora, V K Arora, D Behera, Surya Kant Tripathy
Indian Journal of Tuberculosis, doi:10.1016/j.ijtb.2020.07.031
A group of senior doctors with vast clinical experience met on 19th July'20 under the aegis of Academy of Advanced Medical Education. The panel looked at Ivermectin, one of the old molecule and evaluated it's use in COVID 19 (Novel Coronavirus Disease 2019) management. After critical panel discussion, all the attending doctors came to a conclusion that Ivermectin can be a potential molecule for prophylaxis and treatment of people infected with Coronavirus, owing to its anti-viral properties coupled with effective cost, availability and good tolerability and safety.
Author's contributions All authors provided critical feedback and contributed to the final manuscript.
Declaration of Competing Interest The authors have none to declare.
References
Banerjee, Nandy, Dalai, Ahmed, The battle against COVID 19 pandemic: what we need to know before we "test fire, Ivermectin. Drug Res,
doi:10.1055/a-1185-8913Caly, Druce, Catton, Jans, Wagstaff, The FDAapproved drug ivermectin inhibits the replication of SARS
Cherian, Agrawal, Basu, Abraham, Gangakhedkar et al., Perspectives for repurposing drugs for the coronavirus disease 2019, Indian J Med Res,
doi:10.4103/ijmr.IJMR_585_20Chowdhury, Shahbaz, Karim, Islam, Dan et al., A comparative observational study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients
David, What is the role of antiparasitic drug ivermectin in the treatment of corona virus disease
Gupta, Sahoo, Singh, Ivermectin: potential candidate for the treatment of Covid 19, Braz J Infect Dis
Guzzo, Furtek, Porras, Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects, J Clin Pharmacol,
doi:10.1177/009127002401382731Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot,
doi:10.1038/s41429-020-0336-zMah Evas, Tran, Roumier, Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data, BMJ,
doi:10.1136/bmj.m1844Patel, Desai, Grainger, Mehra, Usefulness of Ivermectin in COVID-19 Illness
Rajter, Sherman, Fatteh, Vogel, Sacks et al., ICON (Ivermectin in COvid Nineteen) study: use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19,
doi:10.1101/2020.06.06.20124461Sharun, Dhama, Patel, Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19, Ann Clin Microbiol Antimicrob,
doi:10.1186/s12941-020-00368-wSinhaa, Sehgalb, Sehgala, Ivermectin: is it to Be a potent therapeutic option for COVID-19?, Clin Infect Immun,
doi:10.14740/cii106Vora, Arora, Behera Academy of Advanced Medical Education
DOI record:
{
"DOI": "10.1016/j.ijtb.2020.07.031",
"ISSN": [
"0019-5707"
],
"URL": "http://dx.doi.org/10.1016/j.ijtb.2020.07.031",
"alternative-id": [
"S0019570720301025"
],
"author": [
{
"affiliation": [],
"family": "Vora",
"given": "Agam",
"sequence": "first"
},
{
"affiliation": [],
"family": "Arora",
"given": "V.K.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Behera",
"given": "D.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Tripathy",
"given": "Surya Kant",
"sequence": "additional"
}
],
"container-title": "Indian Journal of Tuberculosis",
"container-title-short": "Indian Journal of Tuberculosis",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2020,
8,
18
]
],
"date-time": "2020-08-18T12:33:38Z",
"timestamp": 1597754018000
},
"deposited": {
"date-parts": [
[
2022,
11,
7
]
],
"date-time": "2022-11-07T21:04:21Z",
"timestamp": 1667855061000
},
"funder": [
{
"DOI": "10.13039/100007028",
"doi-asserted-by": "publisher",
"name": "Helmsley Charitable Trust"
}
],
"indexed": {
"date-parts": [
[
2023,
10,
12
]
],
"date-time": "2023-10-12T01:28:25Z",
"timestamp": 1697074105687
},
"is-referenced-by-count": 17,
"issue": "3",
"issued": {
"date-parts": [
[
2020,
7
]
]
},
"journal-issue": {
"issue": "3",
"published-print": {
"date-parts": [
[
2020,
7
]
]
}
},
"language": "en",
"license": [
{
"URL": "https://www.elsevier.com/tdm/userlicense/1.0/",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2020,
7,
1
]
],
"date-time": "2020-07-01T00:00:00Z",
"timestamp": 1593561600000
}
}
],
"link": [
{
"URL": "https://api.elsevier.com/content/article/PII:S0019570720301025?httpAccept=text/xml",
"content-type": "text/xml",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://api.elsevier.com/content/article/PII:S0019570720301025?httpAccept=text/plain",
"content-type": "text/plain",
"content-version": "vor",
"intended-application": "text-mining"
}
],
"member": "78",
"original-title": [],
"page": "448-451",
"prefix": "10.1016",
"published": {
"date-parts": [
[
2020,
7
]
]
},
"published-print": {
"date-parts": [
[
2020,
7
]
]
},
"publisher": "Elsevier BV",
"reference": [
{
"DOI": "10.1177/2150132720939402",
"article-title": "COVID-19 pandemic in India: present scenario and a steep climb ahead",
"author": "Pal",
"doi-asserted-by": "crossref",
"journal-title": "J Prim Care Commun Health",
"key": "10.1016/j.ijtb.2020.07.031_bib1",
"volume": "11",
"year": "2020"
},
{
"DOI": "10.14740/cii106",
"article-title": "Ivermectin: is it to Be a potent therapeutic option for COVID-19?",
"author": "Sinhaa",
"doi-asserted-by": "crossref",
"first-page": "51",
"issue": "2",
"journal-title": "Clin Infect Immun",
"key": "10.1016/j.ijtb.2020.07.031_bib2",
"volume": "5",
"year": "2020"
},
{
"DOI": "10.1186/s12941-020-00368-w",
"article-title": "Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19",
"author": "Sharun",
"doi-asserted-by": "crossref",
"first-page": "23",
"issue": "1",
"journal-title": "Ann Clin Microbiol Antimicrob",
"key": "10.1016/j.ijtb.2020.07.031_bib3",
"volume": "19",
"year": "2020"
},
{
"DOI": "10.1016/j.antiviral.2020.104787",
"article-title": "The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro",
"author": "Caly",
"doi-asserted-by": "crossref",
"first-page": "104787",
"journal-title": "Antiviral Res",
"key": "10.1016/j.ijtb.2020.07.031_bib4",
"volume": "178",
"year": "2020"
},
{
"article-title": "The battle against COVID 19 pandemic: what we need to know before we “test fire” Ivermectin",
"author": "Banerjee",
"journal-title": "Drug Res (Stuttg)",
"key": "10.1016/j.ijtb.2020.07.031_bib5",
"year": "2020"
},
{
"author": "Chowdhury",
"key": "10.1016/j.ijtb.2020.07.031_bib6"
},
{
"DOI": "10.4103/ijmr.IJMR_585_20",
"article-title": "Perspectives for repurposing drugs for the coronavirus disease 2019",
"author": "Cherian",
"doi-asserted-by": "crossref",
"first-page": "160",
"issue": "2 & 3",
"journal-title": "Indian J Med Res",
"key": "10.1016/j.ijtb.2020.07.031_bib8",
"volume": "151",
"year": "2020"
},
{
"article-title": "Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data",
"author": "Mahévas",
"first-page": "m2328",
"journal-title": "BMJ",
"key": "10.1016/j.ijtb.2020.07.031_bib9",
"volume": "369",
"year": "2020"
},
{
"article-title": "Targeted Update: safety and efficacy of hydroxychloroquine or chloroquine for treatment of COVID-19",
"journal-title": "WHO",
"key": "10.1016/j.ijtb.2020.07.031_bib10",
"year": "2020"
},
{
"DOI": "10.1152/physrev.00020.2020",
"article-title": "SARS-CoV-2 and COVID-19: from the Bench to the bedside",
"author": "Romagnoli",
"doi-asserted-by": "crossref",
"journal-title": "Physiol Rev",
"key": "10.1016/j.ijtb.2020.07.031_bib11",
"volume": "100",
"year": "2020"
},
{
"article-title": "Ivermectin: potential candidate for the treatment of Covid 19",
"author": "Gupta",
"first-page": "30081",
"issue": "20",
"journal-title": "Braz J Infect Dis",
"key": "10.1016/j.ijtb.2020.07.031_bib12",
"volume": "S1413–8670",
"year": "2020"
},
{
"author": "Clinical Trials Registry- India",
"key": "10.1016/j.ijtb.2020.07.031_bib13"
},
{
"DOI": "10.1177/009127002401382731",
"article-title": "Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects",
"author": "Guzzo",
"doi-asserted-by": "crossref",
"first-page": "1122",
"issue": "10",
"journal-title": "J Clin Pharmacol",
"key": "10.1016/j.ijtb.2020.07.031_bib14",
"volume": "42",
"year": "2002"
},
{
"author": "Drugs@FDA: FDA-Approved Drugs",
"key": "10.1016/j.ijtb.2020.07.031_bib15"
},
{
"author": "Cennimo",
"key": "10.1016/j.ijtb.2020.07.031_bib18"
},
{
"author": "Rajter",
"key": "10.1016/j.ijtb.2020.07.031_bib19"
},
{
"author": "Patel",
"key": "10.1016/j.ijtb.2020.07.031_bib20",
"series-title": "Usefulness of Ivermectin in COVID-19 Illness",
"year": "2020"
},
{
"article-title": "To study the effectiveness of Ivermectin with standard of care treatment versus standard of care treatment for COVID 19 cases",
"journal-title": "A Pilot Study",
"key": "10.1016/j.ijtb.2020.07.031_bib22",
"year": "2019"
},
{
"article-title": "Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen",
"author": "Heidary",
"first-page": "1",
"journal-title": "J Antibiot (Tokyo)",
"key": "10.1016/j.ijtb.2020.07.031_bib23",
"year": "2020"
}
],
"reference-count": 19,
"references-count": 19,
"relation": {},
"resource": {
"primary": {
"URL": "https://linkinghub.elsevier.com/retrieve/pii/S0019570720301025"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "White paper on Ivermectin as a potential therapy for COVID-19",
"type": "journal-article",
"volume": "67"
}
